198 related articles for article (PubMed ID: 34134578)
1. Integrated analysis reveals the participation of IL4I1, ITGB7, and FUT7 in reshaping the TNBC immune microenvironment by targeting glycolysis.
Xu T; Liu J; Xia Y; Wang Z; Li X; Gao Q
Ann Med; 2021 Dec; 53(1):916-928. PubMed ID: 34134578
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
3. Immune microenvironment of the gene signature reflecting the standardised uptake value on
Han S; Oh JS; Kim JS
Ann Nucl Med; 2021 Jan; 35(1):65-75. PubMed ID: 33044632
[TBL] [Abstract][Full Text] [Related]
4. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
[TBL] [Abstract][Full Text] [Related]
5.
Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Arihiro K; Okada M
Anticancer Res; 2023 Jan; 43(1):127-136. PubMed ID: 36585209
[TBL] [Abstract][Full Text] [Related]
6. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.
Zhou Y; Che Y; Fu Z; Zhang H; Wu H
Front Public Health; 2022; 10():902378. PubMed ID: 35875026
[TBL] [Abstract][Full Text] [Related]
7.
Mitchell KG; Amini B; Wang Y; Carter BW; Godoy MCB; Parra ER; Behrens C; Villalobos P; Reuben A; Lee JJ; Weissferdt A; Moran CA; Fujimoto J; Sepesi B; Walsh GL; Vaporciyan AA; Hofstetter WL; William WN; Gibbons DL; Wang J; Hwu P; Swisher SG; Piwnica-Worms D; Kadara H; Wistuba II; Heymach JV; Peng W; Cascone T
Cancer Immunol Immunother; 2020 Aug; 69(8):1519-1534. PubMed ID: 32300858
[TBL] [Abstract][Full Text] [Related]
8. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
[TBL] [Abstract][Full Text] [Related]
9. Tumor Metabolic Features Identified by
Na KJ; Choi H
J Nucl Med; 2018 Jan; 59(1):31-37. PubMed ID: 28588149
[TBL] [Abstract][Full Text] [Related]
10. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.
Koo HR; Park JS; Kang KW; Han W; Park IA; Moon WK
Eur Radiol; 2015 Nov; 25(11):3314-21. PubMed ID: 25903708
[TBL] [Abstract][Full Text] [Related]
11. New insight on the correlation of metabolic status on
Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
[TBL] [Abstract][Full Text] [Related]
12. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
Front Immunol; 2022; 13():967277. PubMed ID: 36466837
[TBL] [Abstract][Full Text] [Related]
13. Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer.
Chen X; Li Z; Liang M; Zhang Z; Zhu D; Lin B; Zhou R; Lu Y
World J Surg Oncol; 2023 Jun; 21(1):194. PubMed ID: 37391802
[TBL] [Abstract][Full Text] [Related]
14. An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer.
Li XF; Fu WF; Zhang J; Song CG
BMC Cancer; 2022 Jun; 22(1):619. PubMed ID: 35668369
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
[TBL] [Abstract][Full Text] [Related]
16. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive Classification of Human Triple Negative Breast Cancer by PET Imaging with GRP78-Targeted Molecular Probe [
Zhao H; Meng H; Wen J; Wang C; Liu J; Huang G
Mol Imaging Biol; 2020 Jun; 22(3):772-779. PubMed ID: 31452065
[TBL] [Abstract][Full Text] [Related]
18. Tumor metabolism and perfusion ratio assessed by 18F-FDG PET/CT and DCE-MRI in breast cancer patients: Correlation with tumor subtype and histologic prognostic factors.
An YS; Kang DK; Jung YS; Han S; Kim TH
Eur J Radiol; 2015 Jul; 84(7):1365-70. PubMed ID: 25886700
[TBL] [Abstract][Full Text] [Related]
19. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.
Yue Y; Cui X; Bose S; Audeh W; Zhang X; Fraass B
Breast Cancer Res Treat; 2015 Oct; 153(3):607-16. PubMed ID: 26346756
[TBL] [Abstract][Full Text] [Related]
20. High expression of IL4I1 is correlated with poor prognosis and immune infiltration in thyroid cancer.
Zhu L; Wang J; Hu J
BMC Endocr Disord; 2023 Jul; 23(1):148. PubMed ID: 37434155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]